CLAIMS

What is claimed is:

- 1. A composition for treating an autoimmune disease, comprising a therapeutically effective amount of a CD40 antagonist in a pharmaceutically acceptable carrier.
- 2. The composition of claim 1, wherein said CD40 antagonist is small molecule.
 - 3. The composition of claim 1, wherein said CD40 antagonist is a protein.
 - 4. The composition of claim 1, wherein said CD40 antagonist is an antibody.
- 5. The composition of claim 1, wherein said CD40 antagonist is a monoclonal antibody.
- 6. The composition of claim 1, wherein said CD40 antagonist is a humanized monoclonal antibody.
- 7. The composition of claim 1, wherein said CD40 antagonist is a human monoclonal antibody.
- 8. The composition of claim 1, wherein said CD40 antagonist is antibody 5H7.
 - 9. The composition of claim 1, wherein said autoimmune disease is psoriasis.

- 10. A method of treating a mammal afflicted with an autoimmune disease, comprising administering to said mammal a therapeutically effective amount of a CD40 antagonist thereby reducing the severity of said autoimmune disease.
- 11. The method of claim 10, wherein said antagonist blocks the interaction between CD40 and CD40L.
- 12. The method of claim 10, wherein said antagonist is an antibody that binds to CD40.
 - 13. The method of claim 10, wherein said antibody is a monoclonal antibody.
- 14. The method of claim 10, wherein said antibody is a humanized monoclonal antibody.
- 15. The method of claim 10, wherein said antibody is a human monoclonal antibody.
 - 16. The method of claim 10, wherein said antibody is 5H7.
- 17. The method of claim 10, wherein said antagonist is a fragment of antibody 5H7.
- 18. The method of claim 10, wherein said autoimmune disease is a T-cell-mediated inflammatory skin disease.
 - 19. The method of claim 10, wherein said autoimmune disease is psoriasis.

- 20. The method of claim 10, wherein said mammal is human.
- 21. The method of claim 10, wherein said CD40 antagonist is administered intraperitoneally or intradermally.
- 22. A method of treating a mammal afflicted with a neoplastic disease, comprising administering to said mammal a therapeutically effective amount of a CD40 antagonist thereby reducing the severity of said neoplastic disease.
- 23. A method of treating a mammal afflicted with psoriasis, comprising administering to said mammal a therapeutically effective amount of a CD40 antagonist.